Results 61 to 70 of about 602,267 (275)

Cyclic thrombocytopenia with statistically significant neutrophil oscillations

open access: yesClinical Case Reports, 2018
Key Clinical Message Cyclic thrombocytopenia is often misdiagnosed as immune thrombocytopenia due to similar clinical features, a fact of significance because cyclic thrombocytopenia generally responds poorly to treatments used successfully in immune ...
Gabriel P. Langlois   +5 more
doaj   +1 more source

Nanoagonist‐mediated spatiotemporal reprogramming of macrophage phenotypes to potentiate tumor immunotherapy

open access: yesBMEMat, EarlyView.
This review systematically summarizes the major molecular mechanisms governing TAM polarization and their coordinated interactions. It further highlights recent advances in nanoagonist‐based strategies that intervene in these pathways to reprogram TAMs, critically discussing their therapeutic potential, current limitations, and translational prospects.
Siqi Fang   +7 more
wiley   +1 more source

Population Pharmacokinetics and Exposure‐Response Analyses to Support Cofetuzumab Pelidotin (ABBV‐647) Dose Optimization in Non‐Small Cell Lung Cancer Patients

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Cofetuzumab pelidotin (Cofe‐P) is an anti‐protein tyrosine kinase 7 (PTK7) antibody‐drug conjugate (ADC) being investigated for the treatment of adults with PTK7‐expressing, recurrent non‐small cell lung cancer (NSCLC). The first‐in‐human (FIH) trial demonstrated tolerability of dosages ≤ 2.8 mg/kg once every 3 weeks (Q3W) and ≤ 3.2 mg/kg Q2W ...
Carla Biesdorf   +8 more
wiley   +1 more source

Oral Azacitidine Maintenance After CPX‐351 in Transplant‐Ineligible Patients With Therapy‐Related or Myelodysplasia‐Related Acute Myeloid Leukemia

open access: yes
American Journal of Hematology, EarlyView.
Caroline Fileni   +18 more
wiley   +1 more source

Clinical Outcomes of Gemcitabine Plus Nab‐Paclitaxel‐Based Chemoradiotherapy in a Multidisciplinary Treatment Strategy for Locally Advanced Pancreatic Cancer (NUPAT‐05): A Prospective, Single‐Arm, Phase II Study

open access: yesInternational Journal of Cancer, EarlyView.
ABSTRACT Although chemoradiotherapy (CRT) has exhibited activity against locally advanced pancreatic cancer (LAPC), no standard regimen has been established. We previously completed a Phase I trial of CRT with gemcitabine plus nab‐paclitaxel (GnP) and established the recommended dose.
Hironori Yamada   +20 more
wiley   +1 more source

New insights into the genetics of congenital neutropenia

open access: yesTurkish Journal of Hematology, 2009
Several congenital disorders may cause neutropenia. The recent advances in the field of molecular biology have facilitated our knowledge concerning pathophysiological mechanisms leading to these disorders.
Namık Özbek
doaj  

Early Chidamide Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation in High‐Risk Myeloid Malignancies: A Prospective Cohort With Time‐Dependent External‐Control Analysis

open access: yesInternational Journal of Cancer, EarlyView.
ABSTRACT Chidamide is an oral histone deacetylase inhibitor whose use as early maintenance after allogeneic hematopoietic stem cell transplantation (HSCT) remains insufficiently defined. This prospective single‐center Phase 1/2 cohort included all 47 patients enrolled and treated by March 31, 2026.
Haonan Yang   +9 more
wiley   +1 more source

Neutropenia in Iranian patients with primary immunodeficiency disorders

open access: yesHaematologica, 2005
Neutropenia may occur in some of the primary immunodeficiency disorders. We reviewed the records of 56 neutropenic patients. The most common disorders were Shwachman-Diamond syndrome, cyclic neutropenia, Kostmann disease, Chediak-Higashi syndrome, hyper ...
N Rezaei   +6 more
doaj  

Chemotherapy After Resection of Pancreatic Ductal Adenocarcinoma: Impact of Different Regimens in a Real‐World Population

open access: yesJournal of Surgical Oncology, EarlyView.
ABSTRACT Introduction The PRODIGE 24/CCTG PA.6‐ trial has shown an overall survival (OS) up to 55 months in patients treated with (modified) 5‐fluorouracil, leucovorin, irinotecan and oxaliplatin ((m)FOLFIRINOX) chemotherapy after resection of pancreatic ductal adenocarcinoma (PDAC). The applicability of these results to a real‐world patient population
N. C. Biesma   +7 more
wiley   +1 more source

Giant Cell Arteritis which Developed after the Administration of Granulocyte-colony Stimulating Factor for Cyclic Neutropenia [PDF]

open access: yes, 2016
A 78-year-old woman diagnosed with cyclic neutropenia 5 years previously had been treated with recombinant granulocyte-colony stimulating factor (G-CSF).
Yasuko Hirai   +31 more
core   +2 more sources

Home - About - Disclaimer - Privacy